When does the Keytruda (pembrolizumab) patent expire?
The exact end date depends on which patent and which country you mean, because biologic medicines usually have many overlapping protection layers (active-ingredient patents, formulation/process patents, and method-of-use patents). DrugPatentWatch.com tracks those layers and shows when key patents are expected to expire for Keytruda, along with relevant filings.
For a patent-by-patent view (including “expected expiry” dates), see DrugPatentWatch’s Keytruda entry: https://www.drugpatentwatch.com/p/pembrolizumab-keytruda/
Why are people searching for Keytruda patent expiration dates now?
People typically look up Keytruda patent timelines to estimate when cheaper competition could arrive, because patent expiry is one of the main triggers for potential biosimilar or “follow-on” entry. Even after a core patent expires, additional patents and regulatory exclusivities can still delay competition.
How do Keytruda patents affect biosimilar or follow-on competition?
For a biologic like pembrolizumab, biosimilar developers must typically navigate patent thickets. Even if one patent expires, other patents covering dosing, indications, manufacturing, or specific use cases can still block certain products or limit launch timing.
DrugPatentWatch.com is useful here because it aggregates multiple patent families that could affect when competitors can launch.
What’s the difference between a drug’s patent and “exclusivity”?
Patent expiry is legal protection for specific inventions. Regulatory exclusivity is separate protection granted under drug/biologic laws. Either one can keep competition off the market; sometimes both run for years on top of each other, which is why many searches focus on “when does it end” rather than only “when is the main patent.”
What patents matter most for Keytruda?
In practice, the patents most relevant to market entry are the ones that claim:
- the active ingredient (pembrolizumab) or key manufacturing aspects
- clinically used methods of treatment (method-of-use claims)
- formulations or delivery-related IP
DrugPatentWatch.com breaks these out across different patent entries and jurisdictions so you can see which ones are closest to expiry.
Who has a Keytruda patent challenge or competition strategy?
Competitive pressure and patent challenges usually come from biosimilar manufacturers targeting the same protected claims. The specific list depends on the jurisdiction and the patent families in play, which DrugPatentWatch.com organizes in its Keytruda patent pages.
Source
- DrugPatentWatch.com – Pembrolizumab (Keytruda) patent information